ClinicalTrials.gg
Not yet recruitingNCT07857135Updated Oct 5, 2026

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors

A Phase 1/2 interventional study of SYS6088 and Regorafenib in Advanced/Metastatic Solid Tumors, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1/2, Interventional, and Treatment

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a multi-center, open-label, dose-escalation, dose-expansion, and cohort-expansion first-in-human Phase 1/2 study to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor efficacy of SYS6088 in patients with advanced/metastatic solid tumors.

02

Conditions studied

  • Advanced/Metastatic Solid Tumors

Browse trials for

Keywords

  • SYS6088, PD-1, CTLA-4, VEGF, Trispecific antibody, tumor
03

In context

Neoplasms

10,834 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 140 is above the median of 60 across 7,712 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 42 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Malignant solid tumors confirmed by histology or cytology
  3. Patients who have failed standard anti-tumor treatment (disease progression or intolerance), have no available standard treatment or refuse standard treatment. (Phase 1)
  4. At least one that meets 1.1 criteria at baseline (the measurable lesion area has not received radiotherapy previously, or there is evidence that the lesion has clearly progressed after the end of radiotherapy) exists
  5. PS score ranges 0-1
  6. Expected survival period ≥ 3 months
  7. Adequate organ function.
  8. Participants must give to this study before the trial and voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of severe allergies; Known or intolerance to any component of the antibody drug and its ;
  2. Subjects with central nervous system or meningeal metastasis. Patients who have undergone targeted radiotherapy or surgical treatment and have no clinical symptoms and signs without drug symptomatic treatment can be enrolled;
  3. Patients with tumor invasion of important arteries leading to high risk of bleeding, obvious risk of perforation, or fistula formation; presence of diseases with impaired wound healing ability;
  4. Uncontrolled pleural effusion, pericardial effusion, or ascites that requires repeated drainage;
  5. Adverse reactions of previous anti-tumor treatment (including radiotherapy) have not recovered to 6.0 ≤ Grade 1;
  6. Occurrence of grade ≥3 immune-related adverse events (irAEs), or treatment discontinuation due to immune-related adverse events previously.
  7. Diagnosed with a second primary malignant tumor within 5 years before the first administration of the study drug; Except for effectively treated basal cell carcinoma of skin, squamous cell carcinoma of skin, and/or effectively resected cervix cancer and/or breast cancer in situ;
  8. Received chemotherapy, biological therapy, targeted therapy and other anti-tumor treatments within 21 days before the first administration of the study drug;
  9. Received live or within 28 days prior to the first administration of study drug or planned to receive during the study;
  10. Use of drugs within 14 days before the first administration of study drug;
  11. Use drugs with anticoagulant effects within 14 days before the first administration of study drug.
  12. Received palliative treatment for local lesions (including local radiotherapy or other local treatments) within 14 days before the first administration of study drug;
  13. Have undergone major surgery (excluding puncture ) or severe traumatic injury 28 days before the first administration of study drug;
  14. Subjects with a history of severe cardiovascular disease;
  15. History or presence of interstitial pneumonia/lung disease;
  16. History or presence of inflammatory bowel disease
  17. History of diseases;
  18. History of immunodeficiency, including positive test, or other acquired or congenital immunodeficiency diseases, or organ transplantation;
  19. Infectious diseases requiring systemic anti-infective treatment;
  20. Active ; infection; Active syphilis infection, active tuberculosis;
  21. Lactating or pregnant women; women of have a positive blood pregnancy test within 7 days prior to trial enrollment; [A participant is of childbearing potential (judged by the investigator) when he/she is biologically capable of fathering a child and is sexually active. Female participants who are not of childbearing potential (i.e., meet at least 1 of the following criteria): have had a hysterectomy or bilateral oophorectomy, or have medically confirmed ovarian failure, or are medically confirmed (cessation of menses for at least 12 consecutive months without a pathological or physiological cause).]
  22. Any male and female participants of childbearing potential who refuse to use effective methods throughout the trial and within half a year after the last administration;
  23. Other conditions that the investigator believes will affect the safety or compliance of the study drug treatment, including but not limited to: mental illness, any severe or uncontrolled disease, etc
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    SYS6088-Phase Ⅰ

    Phase Ⅰ

    Drug: SYS6088

  • Experimental
    SYS6088 dose 1-cohort 1 of Phase Ⅱ

    cohort 1 of Phase Ⅱ

    Drug: SYS6088

  • Experimental
    SYS6088 dose 2-cohort 1 of Phase Ⅱ

    cohort 1 of Phase Ⅱ

    Drug: SYS6088

  • Active comparator
    Regorafenib

    cohort 1 of Phase Ⅱ

    Drug: Regorafenib

  • Experimental
    SYS6088 dose 1-cohort 2 of Phase Ⅱ

    cohort 2 of Phase Ⅱ

    Drug: SYS6088

  • Experimental
    SYS6088 dose 2-cohort 2 of Phase Ⅱ

    cohort 2 of Phase Ⅱ

    Drug: SYS6088

  • Experimental
    SYS6088 dose 1

    cohort 3 of Phase Ⅱ

    Drug: SYS6088

  • Experimental
    SYS6088 dose 2-cohort 3 of Phase Ⅱ

    cohort 3 of Phase Ⅱ

    Drug: SYS6088

  • Experimental
    SYS6088

    cohort 4 of Phase Ⅱ

    Drug: SYS6088

  • Active comparator
    Ivonescimab

    cohort 4 of Phase Ⅱ

    Drug: Ivonescimab

Interventions

  • DrugSYS6088

    SYS6088, administered per protocol.

  • Regorafenib, administered per protocol.

  • Ivonescimab, administered per protocol.

06

What researchers measure

Primary outcomes

  1. The occurrence and frequency of Dose-limiting toxicities (DLTs) DLTs during the study

    Phase Ⅰ

    Time frame: Up to 90 days after last administration

  2. The occurrence and frequency of Treatment-emergent adverse events (TEAEs)

    Phase Ⅰ

    Time frame: Up to 90 days after last administration

  3. The maximum tolerated dose (MTD) of SYS6088 (MTD, if any)

    Phase Ⅰ

    Time frame: Up to approximately 18 weeks after the first participant is enrolled

  4. The recommended Phase 2 dose (RP2D) of SYS6088

    Phase Ⅰ

    Time frame: Up to approximately 36 weeks after the first participant is enrolled

  5. Objective remission rate (ORR) assessed by the investigator according to RECIST v1.1

    Phase Ⅱ

    Time frame: Up to approximately 3 years

  6. The occurrence and frequency of TEAEs

    Phase Ⅱ

    Time frame: Up to 90 days after last administration

Secondary outcomes

  1. Plasma concentration and pharmacokinetic parameters after single and multiple doses ofSYS6088

    Phase l,Cmax

    Time frame: Up to 30 days after last administration

  2. Plasma concentration and pharmacokinetic parameters after single and multiple doses ofSYS6088

    Phase l, Tmax etc.

    Time frame: Up to 30 days after last administration

  3. The incidence and titer of Anti-SYS6088 antibody (if applicable);

    Phase Ⅰ

    Time frame: Up to 30 days after last administration

  4. The titer of Anti-SYS6088 neutralizing antibody (if applicable);

    Phase Ⅰ

    Time frame: Up to 30 days after last administration

  5. Objective response rate (ORR) as assessed by the investigator per RECIST v1.1;

    Phase Ⅰ

    Time frame: Up to 30 days after last administration

  6. Progression-free survival (PFS) as assessed by the investigator per RECIST v1.1

    Phase Ⅰ

    Time frame: Up to approximately 3 years

  7. Disease control rate (DCR) as assessed by the investigator per RECIST v1.1

    Phase Ⅰ

    Time frame: Up to approximately 3 years

  8. Duration of response (DoR) as assessed by the investigator per RECIST v1.1;

    Phase Ⅰ

    Time frame: Up to approximately 3 years

  9. Time to response (TTR) as assessed by the investigator per RECIST v1.1

    Phase Ⅰ

    Time frame: Up to approximately 3 years

  10. Overall survival (OS)

    Duration from the date of initial treatment to the date of death due to any cause

    Time frame: Up to approximately 5 years

  11. DCR assessed by the investigator according to RECIST v1.1;

    Phase Ⅱ

    Time frame: Up to approximately 3 years

  12. PFS assessed by the investigator according to RECIST v1.1

    Phase Ⅱ

    Time frame: Up to approximately 3 years

  13. DoR assessed by the investigator according to RECIST v1.1;

    Phase Ⅱ

    Time frame: Up to approximately 3 years

  14. TTR assessed by the investigator according to RECIST v1.1

    Phase Ⅱ

    Time frame: Up to approximately 3 years

  15. OS

    Duration from the date of initial treatment to the date of death due to any cause

    Time frame: Up to approximately 5 years

  16. The incidence and titer of Anti-SYS6088 antibody (if applicable);

    Phase Ⅱ

    Time frame: Up to 30 days after last administration

  17. The titer of Anti-SYS6088 neutralizing antibody (if applicable);

    Phase Ⅱ

    Time frame: Up to 30 days after last

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Feb 2029, 28 months later.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 28 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2026
First posted
Oct 5, 2026
StartEst.
Oct 3, 2026
Primary completionEst.
Feb 3, 2029
CompletionEst.
Aug 3, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07857135
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Oct 3, 2026 (estimated)
Primary completion
Feb 3, 2029 (estimated)
Completion
Aug 3, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
031169085587

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion